GLOBAL HEALTHCARE TRANSACTIONS AND BUSINESS STRATEGY

Biotrin

  • Requested by Board and VC investors to engineer an exit route from this Dublin-based clinical diagnostics company
  • Assisted company to increase US-based market share
  • Developed IM and identified several acquirers, obtaining term sheets
  • VIEW CASE STUDY

    Cytomyx

  • Biotech drug discovery company quoted on AIM market of the London Stock Exchange
  • Board sought to divest company to realize cash return in light of depressed market capitalisation
  • Sage identified Serologicals (now part of Millipore)
  • VIEW CASE STUDY

    Noven

  • Noven, a specialty neuro pharma company, engaged Sage to assist it in a buyside transaction
  • Objectives were specified as increasing revenue, requirement for an expanded sales infrastructure and enhanced product pipeline in the neuro space
  • Sage assembled an initial long shortlist and honed this down to 6 candidates in conjunction with Novens Board
  • VIEW CASE STUDY

    Life Science Resources

  • Assisted in founding of company involved in photonics and biological imaging for high throughput drug discovery and proteomics
  • Assisted in fund raising and technology/IP development
  • Developed high profile OEM and technology access relationship programmes with Amersham, EGG Wallac, Olympus USA, Olympus Japan, Olympus Europe and Perkin Elmer
  • VIEW CASE STUDY

    NatImmune

  • Tired investors desiring a partnership of the lead protein replacement technology before further supporting the company
  • Sage engaged Enzon as well as three other parties
  • Closed a deal with $10 mil. in upfront fees and potential milestones of over $100 mil.
  • VIEW CASE STUDY

    Biotrin

  • Requested by Board and VC investors to engineer an exit route from this Dublin-based clinical diagnostics company
  • Assisted company to increase US-based market share
  • View Case Study >

    Cytomyx

  • Biotech drug discovery company quoted on AIM market of the London Stock Exchange
  • Board sought to divest company to realize cash return in light of depressed market capitalisation
  • View Case Study >

    Noven

  • Noven, a specialty neuro pharma company, engaged Sage to assist it in a buyside transaction
  • Objectives were specified as increasing revenue, requirement for an expanded sales infras...
  • View Case Study >

    Life Science Resources

  • Assisted in founding of company involved in photonics and biological imaging for high throughput drug discovery and proteomics
  • Assisted in fund raising and technology/IP development
  • View Case Study >

    NatImmune

  • Tired investors desiring a partnership of the lead protein replacement technology before further supporting the company
  • Sage engaged Enzon as well as three other parties
  • View Case Study >

    RGene Therapeutics

  • Sage assisted in negotiating a $1 million patent license with Pasteur Merieux Connaught
  • Sage assisted in negotiating a $30 million European marketing partnership with Fournier
  • View Case Study >

    SK BioPharmaceuticals

  • Small US biopharm subsidiary of SK Corporation of Korea seeking to out-license an anti-epileptic and anti-depressant in early clinical trials
  • Little or no experience with multi-nati...
  • View Case Study >

    Luminex

  • Sage worked with this imaging/diagnostics company from a startup with 3 employees in a garage
  • Sage wrote the companys first business plan and investment memorandum for a novel diagn...
  • View Case Study >

    Focal

  • Engaged with the company to advise on marketing and regulatory hurdles to develop polymer bioadhesive medical technology as a lung sealant
  • Prepared a detailed valuation model which ...
  • View Case Study >

    NitroMed

  • Sold non-relevant patent right Ohmeda for $1 million within 90 days of getting assignment
  • Internal investors heartened to bridge additional funds
  • View Case Study >

    Cenix

  • Engaged with RNAi biotech company at invitation of principal shareholders
  • Developed IM and divestment strategy to realise exit for investors
  • View Case Study >

    iStat Corporation

  • Served as first President and CEO
  • Developed chemical biosensors in the medical technology space for blood gases and analytes
  • View Case Study >